Analysts expect Syros Pharmaceuticals Inc (NASDAQ:SYRS) to report ($0.45) earnings per share for the current quarter, Zacks reports. Five analysts have provided estimates for Syros Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.35) and the lowest estimate coming in at ($0.54). Syros Pharmaceuticals reported earnings per share of ($0.49) in the same quarter last year, which suggests a positive year over year growth rate of 8.2%. The business is scheduled to issue its next quarterly earnings report on Wednesday, May 6th.
On average, analysts expect that Syros Pharmaceuticals will report full year earnings of ($1.81) per share for the current financial year, with EPS estimates ranging from ($1.98) to ($1.40). For the next financial year, analysts forecast that the company will report earnings of ($1.92) per share, with EPS estimates ranging from ($2.46) to ($1.60). Zacks’ EPS calculations are an average based on a survey of research firms that follow Syros Pharmaceuticals.
Syros Pharmaceuticals (NASDAQ:SYRS) last issued its earnings results on Thursday, March 5th. The company reported ($0.46) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.47) by $0.01. Syros Pharmaceuticals had a negative net margin of 3,806.16% and a negative return on equity of 86.29%. The firm had revenue of $0.51 million during the quarter, compared to the consensus estimate of $0.79 million.
Several equities research analysts recently commented on the stock. ValuEngine upgraded shares of Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, February 25th. Wedbush cut Syros Pharmaceuticals from an “outperform” rating to a “neutral” rating and set a $9.00 price target on the stock. in a research report on Friday, January 17th. BidaskClub cut Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, January 31st. Cowen reiterated a “buy” rating on shares of Syros Pharmaceuticals in a research report on Thursday, March 5th. Finally, HC Wainwright reiterated a “neutral” rating and set a $8.00 price target (down from $10.00) on shares of Syros Pharmaceuticals in a research report on Friday, March 6th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the company. Syros Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $12.54.
SYRS opened at $5.67 on Tuesday. The company’s 50 day moving average is $6.40 and its 200-day moving average is $6.99. Syros Pharmaceuticals has a 1-year low of $4.26 and a 1-year high of $11.93. The company has a debt-to-equity ratio of 0.31, a quick ratio of 4.87 and a current ratio of 4.87.
A number of hedge funds have recently made changes to their positions in SYRS. Tower Research Capital LLC TRC lifted its holdings in shares of Syros Pharmaceuticals by 863.4% in the third quarter. Tower Research Capital LLC TRC now owns 2,688 shares of the company’s stock worth $28,000 after buying an additional 2,409 shares in the last quarter. Bank of Montreal Can increased its stake in Syros Pharmaceuticals by 44.6% during the fourth quarter. Bank of Montreal Can now owns 4,400 shares of the company’s stock worth $30,000 after acquiring an additional 1,357 shares during the last quarter. Citigroup Inc. increased its stake in Syros Pharmaceuticals by 175.0% during the fourth quarter. Citigroup Inc. now owns 10,236 shares of the company’s stock worth $71,000 after acquiring an additional 6,514 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. acquired a new stake in Syros Pharmaceuticals during the fourth quarter worth $77,000. Finally, Trexquant Investment LP acquired a new stake in Syros Pharmaceuticals during the fourth quarter worth $92,000. Hedge funds and other institutional investors own 97.17% of the company’s stock.
Syros Pharmaceuticals Company Profile
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients.
Read More: Ex-Dividend
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.